"What you are claiming is just arrant flim-flam based solely on your own dishonest opinions"
Pot ~Kettle. lol... Maybe learn something, for once??? You don't have to be a member of NICE to know how they operate and what their track record is.
NICE evaluates drugs based on their incremental cost-effectiveness ratio (ICER), which measures the cost per quality-adjusted life year (QALY) gained. Typically, a drug is considered cost-effective if it falls within the range of £20,000 to £30,000 per QALY, .
According to NWBO's phase 3 trial (Which many scientists question) the overall survival is about 16 months vs. 13 months for SOC . In my opinion there is no way NICE will pay an additional 150k - 250K to add 3 months (maybe) of life to a patient's life.
https://remapconsulting.com/funding/how-does-nice-make-cost-effectiveness-decisions-on-medicines-and-what-are-modifiers/
Market Data 
Markets 
